Wonbiogen Co., Ltd. (KOSDAQ:307280)
South Korea
· Delayed Price · Currency is KRW 6,100.00
-210.00 (-3.33%)
At close: Dec 5, 2025
Wonbiogen Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 34,381 | 30,440 | 29,615 | 26,748 | 17,721 | 12,018 |
| Other Revenue | - | -0 | -0 | -0 | -0 | - |
| Revenue | 34,381 | 30,440 | 29,615 | 26,748 | 17,721 | 12,018 |
| Revenue Growth (YoY) | 17.33% | 2.79% | 10.72% | 50.94% | 47.46% | - |
| Cost of Revenue | 17,778 | 16,202 | 15,469 | 14,325 | 10,173 | 7,237 |
| Gross Profit | 16,603 | 14,238 | 14,146 | 12,423 | 7,548 | 4,780 |
| Selling, General & Admin | 8,243 | 6,548 | 5,719 | 5,950 | 4,048 | 1,569 |
| Research & Development | 633.66 | 838.47 | 504.15 | 492.1 | 584.71 | 488.8 |
| Amortization of Goodwill & Intangibles | 55.57 | 55.76 | 68.82 | 67.66 | 63.19 | 60.81 |
| Other Operating Expenses | 51.76 | 49.15 | 39.04 | 36.97 | 55.85 | 28.27 |
| Operating Expenses | 9,190 | 8,022 | 7,108 | 7,372 | 5,508 | 2,288 |
| Operating Income | 7,413 | 6,216 | 7,038 | 5,050 | 2,040 | 2,492 |
| Interest Expense | -45.64 | -57.77 | -116.68 | -1,274 | -430.65 | -665.21 |
| Interest & Investment Income | 268.95 | 304.07 | 279.71 | 128.25 | 47 | 7.09 |
| Earnings From Equity Investments | 37.07 | 42.83 | -60.51 | - | - | - |
| Currency Exchange Gain (Loss) | 142.12 | 150.8 | 49.99 | -44.9 | 42.36 | -3.49 |
| Other Non Operating Income (Expenses) | -146.62 | -3.03 | -74.84 | -4.82 | -2,436 | -13,113 |
| EBT Excluding Unusual Items | 7,668 | 6,653 | 7,115 | 3,855 | -737.83 | -11,282 |
| Gain (Loss) on Sale of Investments | -32.64 | -32.64 | 48.67 | -200 | - | - |
| Gain (Loss) on Sale of Assets | -59.48 | -1.38 | -7.13 | 11.69 | -57.7 | - |
| Asset Writedown | -196.65 | -196.65 | - | - | - | - |
| Pretax Income | 7,380 | 6,422 | 7,157 | 3,667 | -795.53 | -11,282 |
| Income Tax Expense | 1,123 | 1,084 | 1,196 | 394.35 | -135.74 | 380.31 |
| Earnings From Continuing Operations | 6,257 | 5,339 | 5,961 | 3,272 | -659.78 | -11,662 |
| Minority Interest in Earnings | 360.79 | 350.98 | -463.77 | -66.38 | -56.42 | - |
| Net Income | 6,617 | 5,690 | 5,497 | 3,206 | -716.2 | -11,662 |
| Net Income to Common | 6,617 | 5,690 | 5,497 | 3,206 | -716.2 | -11,662 |
| Net Income Growth | 22.87% | 3.50% | 71.46% | - | - | - |
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | 5 |
| Shares Outstanding (Diluted) | 7 | 7 | 8 | 7 | 7 | 5 |
| Shares Change (YoY) | -6.95% | -6.72% | 5.70% | 3.58% | 49.52% | - |
| EPS (Basic) | 932.81 | 801.97 | 783.94 | 450.77 | -104.35 | -2510.13 |
| EPS (Diluted) | 930.43 | 800.00 | 725.00 | 445.00 | -105.00 | -2515.00 |
| EPS Growth | 31.44% | 10.35% | 62.92% | - | - | - |
| Free Cash Flow | 7,110 | 8,201 | 3,189 | -711.95 | -1,254 | 118.77 |
| Free Cash Flow Per Share | 1002.20 | 1155.96 | 419.31 | -98.94 | -180.51 | 25.56 |
| Dividend Per Share | 100.000 | 100.000 | 100.000 | 50.000 | - | - |
| Dividend Growth | - | - | 100.00% | - | - | - |
| Gross Margin | 48.29% | 46.77% | 47.77% | 46.44% | 42.59% | 39.78% |
| Operating Margin | 21.56% | 20.42% | 23.76% | 18.88% | 11.51% | 20.74% |
| Profit Margin | 19.25% | 18.69% | 18.56% | 11.99% | -4.04% | -97.05% |
| Free Cash Flow Margin | 20.68% | 26.94% | 10.77% | -2.66% | -7.08% | 0.99% |
| EBITDA | 8,963 | 7,863 | 8,607 | 6,249 | 2,921 | 3,223 |
| EBITDA Margin | 26.07% | 25.83% | 29.06% | 23.36% | 16.48% | 26.82% |
| D&A For EBITDA | 1,551 | 1,647 | 1,569 | 1,199 | 881.58 | 731.27 |
| EBIT | 7,413 | 6,216 | 7,038 | 5,050 | 2,040 | 2,492 |
| EBIT Margin | 21.56% | 20.42% | 23.76% | 18.88% | 11.51% | 20.74% |
| Effective Tax Rate | 15.22% | 16.87% | 16.71% | 10.75% | - | - |
| Advertising Expenses | - | 1,113 | 881.91 | 1,184 | 700.07 | -4.3 |
Source: S&P Capital IQ. Standard template. Financial Sources.